Loading
A phase 2 trial of Cemiplimab in non-small-cell lung cancer and small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT06465329 by Regeneron Pharmaceuticals, with 120 participants planned, started 2024-11-18 and due to reach its primary completion in 2027-05-20. Interventions recorded: Cemiplimab, Platinum-based chemotherapy, REGN7075. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Regeneron, Cemiplimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares REGN7075, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Immune checkpoint inhibitors.
Shares REGN7075, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/